Drug Trial Radar · NCT04362072
Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer
Last checked: Nov 20, 2026Latest source record: Jun 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
71
Actual
Start
Sep 29, 2020
Primary completion
May 29, 2024
Study completion Oct 23, 2024
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Apr 24, 2020
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this clinical trial is to learn whether the study medicine (called lorlatinib) is safe and effective for the treatment of non-small cell lung cancer that is caused by an abnormal anaplastic lymphoma kinase (ALK) gene. This study is seeking participants whose lung cancer has progressed after receiving either alectinib or ceritinib as their first treatment. Participants will take part in this study for up to approximately 4 years, depending on when the study is completed and how their cancer responds to the study treatment. They will take lorlatinib orally (by mouth) once daily. Participants will visit the study site about every six weeks to meet with the study team. During these visits, the study team will monitor the safety and effects of lorlatinib.
Conditions
- Carcinoma
- Non-Small-Cell Lung
Interventions
LorlatinibDrug
25 milligram (mg) tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Confirmed Overall Objective Response (OR) as Per Independent Central Review (ICR) as Assessed by RECIST v1.1Time frame: From date of first dose until documented PD or start of new anti-cancer therapy, whichever occurred earlier (maximum treatment exposure up to 42.78 months)
Locations
31 sites in 7 countries. Site status is shown where the registry gives one.
UCI Medical Center/Chao Family Comprehensive Cancer Center
Orange, California
Rajiv Gandhi Cancer Institute And Research Centre
New Delhi, DEL, India
Healthcare Global Enterprises
Bengaluru, Karnataka, India
Bhakti Vedanta Hospital and Research Institute
Thane, Maharashtra, India
Rajiv Gandhi Cancer Institute And Research Centre
New Delhi, National Capital Territory of Delhi, India
Azienda Ospedaliera San Giuseppe Moscati
Avellino, Italy
Fondazione IRCCS San Gerardo dei Tintori
Monza, Lombardy, Italy
IRCCS Ospedale San Raffaele
Milan, MI, Italy
Centro Riferimento Oncologico di Aviano - IRCCS SOC Oncologia Medica e dei Tumori Immunocorrelati
Aviano, PN, Italy
Azienda Ospedaliero Universitaria di Parma
Parma, PR, Italy
Azienda Ospedaliera San Camillo Forlanini
Roma, ROME, Italy
AOU San Luigi Gonzaga
Orbassano (TO), TO, Italy
AO Santa Maria della Misericordia
Perugia, Umbria, Italy
Ms Pneumed Janusz Milanowski, Katarzyna Szmygin-Milanowska Spolka Jawna
Lublin, Poland
Centrum Medyczne EVOMED
Szczecin, Poland
Dom Lekarski Centrum Medyczne Outlet Park
Szczecin, Poland
Pracownia Medycyny Nuklearnej, 109 Szpital Wojskowy z Przychodnia SP ZOZ
Szczecin, Poland
Dom Lekarski S.A.
Szczecin, Poland
Hospital Teresa Herrera (C.H.U.A.C)
A Coruña, Spain
Hospital de la Santa Creu i Sant Pau
Barcelona, Spain
Hospital Universitari Vall d'Hebron
Barcelona, Spain
Hospital de la Santa Creu i Sant Pau
Barcelona, Spain
ICO L'Hospitalet (Hospital Duran i Reynals)
L'Hospitalet de Llobregat, Spain
Hospital Regional Universitario de Malaga
Málaga, Spain
Hospital Universitario Virgen del Rocio
Seville, Spain
Hospital Universitari i Politecnic La Fe
Valencia, Spain
Hospital Universitario Puerta de Hierro Majadahonda
Majadahonda, Madrid, Spain
Kantonsspital Graubuenden
Chur, Kanton Graubünden, Switzerland
Guy's and St Thomas' NHS Foundation Trust
London, United Kingdom
NIHR/Wellcome Trust Clinical Research Facility
Manchester, United Kingdom
The Christie NHS Foundation Trust
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.